Partnership Joins Protein Sequencing Technology With AI Visualization to Further Unlock the Human Proteome for Novel Drug Discovery Key Takeaways January 09, 2023 08:00 AM Eastern Standard Time GUILFORD, Conn.–(BUSINESS WIRE)–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with … Read More
Biovista Presentation in NIH’s Predictive Toxicology Branch DNTP
Eftychia Lekka, Ph.D. and Vassilis Virvilis, Ph.D Biovista Efforts to standardize important concepts and relationships using established Terminologies in the AOP Knowledge Base at NIH’s Predictive Toxicology Branch DNTP Seminar on Friday June 24 2022. The presentation will summarize a systematic approach on reviewing and categorizing user-entered data issues in the Adverse Outcome Pathway (AOP) … Read More
Biovista Personalized Medicine and Diginova to deliver next generation AI-driven doctor/patient support in a deal that can generate over $5 Billion.
CHARLOTTESVILLE, Va. and DUBAI, UAE, Sept. 15, 2021 /PRNewswire/ — Biovista Personalized Medicine and Diginova Health Solutions today announced their deal to deliver augmented intelligence (AI)-driven personalized medicine analytics to over a quarter of a billion patients in Asia, starting in the MENA region. Diginova will offer Biovista Personalized Medicine’s market-leading AI Health ShieldTM analytics direct-to-consumer, … Read More
Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19
Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19 CHARLOTTESVILLE, Va., Aug. 25, 2020 /PRNewswire/ — Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced today by Biovista, an AI-driven bioscience firm that … Read More
There is an urgent need for the healthcare industry to reposition safety: that is to change how the ability to discover, possess information about and act on predicted Adverse Drug Reactions (ADR) is perceived and treated by pharma companies, the regulator and other stakeholders. To date drug testing has been biased toward minimizing “Type I” … Read More